Biotechnology

Antogen’s new Oklahoma City lab marks a critical pivot from R&D to revenue, proving that scaling complex biotech no longer requires a coastal zip code.

As its mitochondrial therapeutics near regulatory review, BPGbio appoints M&A expert Jason Krause, signaling a shift toward commercialization or a major exit.

Kane Biotech engages Independent Trading Group to narrow bid-ask spreads, signaling a strategic push to align capital markets with its commercial rollout.

Alejandro Weinstein's buyout of Pluri's EIB debt saves the biotech from default, but concentrates unprecedented power in the chairman's hands.

By programming stem cells into pancreatic beta cells in just four days, Syntax Bio is tackling the biomanufacturing choke point of Type 1 diabetes therapies.

A pending securities class action against Ardelyx highlights the growing collision between lofty biopharma revenue targets and the harsh reality of PBM cost controls.

As AI fatigue sets in, GenesisL1's GL1X platform offers a tangible use case: autonomous LLMs conducting verifiable bioinformatics research on the blockchain.

An abrupt four-director exit and the arrival of M&A veterans suggest PDS Biotechnology is pivoting from clinical research to a lucrative buyout or licensing pact.

Pedro Lichtinger will outline strategies for scaling global biopharmas, spotlighting continuous delivery tech to enhance proven cancer therapies.

As biotech valuations plummet, Yakira Capital is calling out Atrium's board over a highly dilutive $50 million raise. Is it time for a strategic review?

FDA Fast Track designation for a new Alzheimer's vaccine signals a monumental shift from costly symptom management to proactive, active immunization.

By appointing former Pfizer CSO Mikael Dolsten, Maxion Therapeutics signals its readiness to bring its revolutionary KnotBody platform into clinical trials.

Gesynta Pharma just shattered enrollment targets for its Phase 2 endometriosis trial. Here is why this signals a massive shift in biotech investment.

The biotech firm behind the viral Mother Dirt brand brings its live bacteria mist in-house, launching higher-potency formulas for the microbiome market.

French biotech Adocia secures a €7M financing package, lifting its going-concern warning and bridging the gap to a crucial Chinese regulatory approval.

WuXi AppTec just clinched its tenth consecutive Frost & Sullivan award. But can commercial excellence insulate the CRDMO giant from mounting geopolitical friction?

A Dallas biotech firm bought a rare moa egg to return it to New Zealand. Is this a PR stunt, or a new model for indigenous-led scientific de-extinction?

The 2027 MDA Conference agenda reveals a pragmatic shift: leveraging AI, gene therapy, and real-world data to accelerate rare disease drug development.

Moving beyond traditional DNA sequencing, BostonGene’s biologically grounded AI helps oncologists and biopharma uncover hidden cancer resistance mechanisms.

Meredith Manning takes the commercial helm at Genetix Biotherapeutics, tasked with translating FDA-approved gene therapies into real-world patient access.